

# Stefan GlÃ¼ck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11069255/publications.pdf>

Version: 2024-02-01

99  
papers

4,037  
citations

147801

31  
h-index

123424

61  
g-index

100  
all docs

100  
docs citations

100  
times ranked

5732  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e575-e583.	2.4	7
2	Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor- positive metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 2661-2672.	2.4	6
3	Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 5.	2.5	4
4	Immunotherapy in breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 2.	2.5	56
5	Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 249-256.	1.9	21
6	Post-surgical depressive symptoms and long-term survival in non-metastatic breast cancer patients at 11-year follow-up. <i>General Hospital Psychiatry</i> , 2017, 44, 16-21.	2.4	33
7	Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 79-90.	2.4	23
8	Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. <i>Psychosomatic Medicine</i> , 2016, 78, 26-37.	2.0	55
9	Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 113-126.	2.5	79
10	Ethnic differences in types of social support from multiple sources after breast cancer surgery. <i>Ethnicity and Health</i> , 2016, 21, 411-425.	2.5	12
11	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 575.	1.6	28
12	Brief cognitive-behavioral and relaxation training interventions for breast cancer: A randomized controlled trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2015, 83, 677-688.	2.0	78
13	Randomized controlled trial of cognitive behavioral stress management in breast cancer: A brief report of effects on 5-year depressive symptoms.. <i>Health Psychology</i> , 2015, 34, 176-180.	1.6	44
14	A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 319-328.	2.5	91
15	Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting. <i>Clinical Therapeutics</i> , 2015, 37, 134-144.	2.5	13
16	Long-term psychological benefits of cognitive-behavioral stress management for women with breast cancer: 11-year follow-up of a randomized controlled trial. <i>Cancer</i> , 2015, 121, 1873-1881.	4.1	142
17	Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective. <i>Clinical Breast Cancer</i> , 2015, 15, e263-e276.	2.4	21
18	Improved Clinical Outcomes Associated With Vitamin D Supplementation During Adjuvant Chemotherapy in Patients With HER2+ Nonmetastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, e1-e11.	2.4	69

#	ARTICLE	IF	CITATIONS
19	Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy. <i>Medical Oncology</i> , 2014, 31, 163.	2.5	22
20	Participation in Cancer Clinical Trials. <i>Medical Decision Making</i> , 2014, 34, 116-126.	2.4	111
21	Sleep Quality and Fatigue after a Stress Management Intervention for Women with Early-Stage Breast Cancer in Southern Florida. <i>International Journal of Behavioral Medicine</i> , 2014, 21, 971-981.	1.7	56
22	Can mammographic and sonographic imaging features predict the Oncotype DX <sup>®</sup> recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 117-123.	2.5	21
23	Circulating tumor cells in breast cancer. <i>Journal of Carcinogenesis</i> , 2014, 13, 8.	2.5	21
24	Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 433-441.	2.5	17
25	Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor-Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action. <i>Clinical Breast Cancer</i> , 2014, 14, 75-84.	2.4	25
26	nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 221-227.	2.4	32
27	Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 629-629.	1.6	0
28	A comparative effectiveness analysis of single-agent cytotoxics in triple-negative metastatic breast cancer (TN-MBC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17648-e17648.	1.6	0
29	Molecularly targeted therapies for metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 21-35.	2.5	123
30	Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 759-767.	2.5	90
31	A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 187-193.	2.5	25
32	Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. <i>Breast</i> , 2013, 22, 142-149.	2.2	10
33	Nonsteroidal Anti-inflammatory Drug Induced Thrombotic Thrombocytopenic Purpura. <i>Plasmatology</i> , 2013, 6, CMBD.S12843.	0.4	6
34	Molecular Profiling for Breast Cancer: A Comprehensive Review. <i>Biomarkers in Cancer</i> , 2013, 5, BIC.S9455.	3.6	152
35	Macrophages as independent prognostic factors in small T1 breast cancers. <i>Oncology Reports</i> , 2013, 29, 141-148.	2.6	12
36	Biologic Impact and Clinical Implication of mTOR Inhibition in Metastatic Breast Cancer. <i>International Journal of Biological Markers</i> , 2013, 28, 233-241.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in postmenopausal Early Breast Cancer. <i>Clinical Medicine Insights Women's Health</i> , 2013, 6, CMWH.S8692.	0.6	3
38	Treating Breast Cancer in the 21st Century: Emerging Biological Therapies. <i>Journal of Cancer</i> , 2013, 4, 117-132.	2.5	140
39	Ductal carcinoma <i>in situ</i> : how should we treat it?. <i>Breast Cancer Management</i> , 2013, 2, 245-256.	0.2	0
40	Gene expression profiling in breast cancer. <i>American Journal of Translational Research (discontinued)</i> , 2013, 5, 132-8.	0.0	10
41	Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues regarding Dual HER2-Targeted Therapy. <i>Breast Cancer: Basic and Clinical Research</i> , 2012, 6, BCBCR.S9301.	1.1	10
42	Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. <i>Case Reports in Oncology</i> , 2012, 5, 687-692.	0.7	7
43	Using modern molecular markers to tailor breast cancer treatment: a new era for personalized medicine. <i>Breast Cancer Management</i> , 2012, 1, 105-108.	0.2	2
44	HER2-positive metastatic breast cancer: a double-edged sword. <i>Breast Cancer Management</i> , 2012, 1, 181-184.	0.2	1
45	Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S17-S22.	3.4	9
46	Systemic therapy options in BRCA mutation-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 355-366.	2.5	49
47	Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 143-151.	7.7	40
48	Eribulin monotherapy in a patient with heavily pretreated metastatic breast cancer: Case study and review of the literature. <i>Journal of Solid Tumors</i> , 2012, 3, .	0.1	1
49	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine±Trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 781-791.	2.5	194
50	A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 747-751.	2.5	56
51	Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?. <i>Current Oncology Reports</i> , 2012, 14, 1-11.	4.0	77
52	Novel Cytotoxic Agents in the Treatment of Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 2012, 4, 75-82.	1.0	1
53	Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 329-334.	3.1	65
54	Adjuvant Therapy for Early Breast Cancer. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
55	Successful Use of Biweekly Gemcitabine Plus Nab-Paclitaxel in Two Male Patients With Stage IV Breast Cancer: Case Reports and Review of the Literature. <i>American Journal of Therapeutics</i> , 2011, 18, e12-e18.	0.9	3
56	Surviving Metastatic Breast Cancer for 18 Years: A Case Report and Review of the Literature. <i>Breast Journal</i> , 2011, 17, 521-524.	1.0	3
57	Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 431-439.	2.5	16
58	Stress Management Skills and Reductions in Serum Cortisol Across the Year After Surgery for Non-Metastatic Breast Cancer. <i>Cognitive Therapy and Research</i> , 2011, 35, 595-600.	1.9	28
59	Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient. <i>Clinical Cancer Research</i> , 2011, 17, 5559-5561.	7.0	33
60	Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 1699-1706.	1.0	10
61	Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women. <i>Breast Cancer: Basic and Clinical Research</i> , 2011, 5, BCBCR.S6234.	1.1	13
62	Chemotherapy regimens in metastatic breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 47-8.	0.3	0
63	Exemestane as First-Line Therapy in Postmenopausal Women With Recurrent or Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 314-319.	1.3	15
64	Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 427-435.	2.5	76
65	Foreword. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, S1-S2.	4.1	0
66	Rational combinations in metastatic breast cancer: bevacizumab with chemotherapy. <i>Community Oncology</i> , 2010, 7, 253-262.	0.2	0
67	Improving outcomes in early-stage breast cancer. <i>Oncology</i> , 2010, 24, 1-15.	0.5	19
68	A woman's heart. <i>Cancer</i> , 2009, 115, 1813-1826.	4.1	81
69	NOAH Study: Is It Really Setting the New Standard for Preoperative Systemic Therapy in HER2-Positive Early Breast Cancer?. <i>Breast Diseases</i> , 2009, 20, 138-139.	0.0	0
70	Lapatinib Plus Capecitabine Resolved Human Epidermal Growth Factor Receptor 2-Positive Brain Metastases. <i>American Journal of Therapeutics</i> , 2009, 16, 585-590.	0.9	21
71	A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients with HER2-negative Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 162-167.	2.4	11
72	Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. <i>Journal of Clinical Oncology</i> , 2008, 26, 37-43.	1.6	53

#	ARTICLE	IF	CITATIONS
73	Stress Management Intervention Reduces Serum Cortisol and Increases Relaxation During Treatment for Nonmetastatic Breast Cancer. <i>Psychosomatic Medicine</i> , 2008, 70, 1044-1049.	2.0	100
74	XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer. <i>International Journal of Medical Sciences</i> , 2008, 5, 341-346.	2.5	15
75	Gemcitabine and taxanes in metastatic breast cancer: a systematic review. <i>Therapeutics and Clinical Risk Management</i> , 2008, 4, 1157-64.	2.0	9
76	Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 666-72.	0.3	6
77	The Prevention and Management of Distant Metastases in Women with Breast Cancer. <i>Cancer Investigation</i> , 2007, 25, 6-13.	1.3	18
78	Paclitaxel albumin-bound particles (abraxane <sup>®</sup> ) in combination with bevacizumab with or without gemcitabine: Early experience at the University of Miami/Braman Family Breast Cancer Institute. <i>Biomedicine and Pharmacotherapy</i> , 2007, 61, 531-533.	5.6	23
79	How stress management improves quality of life after treatment for breast cancer.. <i>Journal of Consulting and Clinical Psychology</i> , 2006, 74, 1143-1152.	2.0	236
80	The 3rd InterAmerican Breast Cancer Conference Fiesta Americana Grand Coral Beach Hotel, Cancun, Mexico July 27 <sup>th</sup> -29, 2006. <i>Breast Cancer Online: BCO</i> , 2006, 9, 1-2.	0.1	0
81	Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity. <i>Head and Neck</i> , 2006, 28, 189-196.	2.0	24
82	Acceleration of Telomere Loss by Chemotherapy Is Greater in Older Patients with Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6345-6350.	7.0	48
83	How Stress Management Improves Quality of Life After Treatment for Breast Cancer.. <i>Journal of Consulting and Clinical Psychology</i> , 2006, 74, 1143-1152.	2.0	158
84	Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin. <i>Oncologist</i> , 2005, 10, 780-791.	3.7	55
85	Comparison of CD34 and Monocyte-Derived Dendritic Cells from Mobilized Peripheral Blood from Cancer Patients. <i>Stem Cells</i> , 2005, 23, 74-81.	3.2	27
86	New advances in the management of metastatic breast cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3 Suppl 1, S12-6.	4.9	1
87	Priming with Dendritic Cells Can Generate Strong Cytotoxic T Cell Responses to Chronic Myelogenous Leukemia Cells In Vitro. <i>Stem Cells and Development</i> , 2004, 13, 211-221.	2.1	2
88	The Expanding Role of Epirubicin in the Treatment of Breast Cancer. <i>Cancer Control</i> , 2002, 9, 16-27.	1.8	15
89	Generation of dendritic cells: role of cytokines and potential clinical applications. <i>Transfusion and Apheresis Science</i> , 2001, 24, 117-124.	1.0	12
90	Generation of Dendritic Cells Ex Vivo: Differences in Steady State Versus Mobilized Blood from Patients with Breast Cancer, with Lymphoma, and from Normal Donors. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 621-630.	1.8	8

#	ARTICLE	IF	CITATIONS
91	The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer. <i>Breast Cancer</i> , 2001, 8, 321-328.	2.9	5
92	Effects of Cytokines on the Culture and Differentiation of Dendritic Cells In Vitro. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 43-51.	1.8	17
93	Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 231-244.	2.5	38
94	Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 1999, 17, 846-846.	1.6	597
95	Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant mcf-7 breast cancer cells. , 1999, 82, 893-900.		15
96	Bacterial decontamination of blood stem cell apheresis products. <i>Journal of Clinical Apheresis</i> , 1998, 13, 103-107.	1.3	7
97	The Selective Uptake of Benzoporphyrin Derivative Mono-Acid Ring A Results in Differential Cell Kill of Multiple Myeloma Cells in vitro. <i>Photochemistry and Photobiology</i> , 1996, 63, 846-853.	2.5	20
98	Characterization and transfusion of in vitro cultivated hematopoietic progenitor cells. <i>Transfusion Science</i> , 1995, 16, 273-281.	0.6	6
99	Radiosensitivity of human clonogenic myeloma cells and normal bone marrow precursors: Effect of different dose rates and fractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 28, 877-882.	0.8	19